Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Jul 11

PMID 26161666

Citations 21

Authors

Melissa Chan

Martin C Chang

Rosa Gonzalez

Belinda Lategan

Elvira Del Barco

Francisco Vera-Badillo

Paula Quesada

Robyn Goldstein

Ignacio Cruz

Alberto Ocana

Juan J Cruz

Eitan Amir

Affiliations

Soon will be listed here.

Abstract

Purpose: To describe the clinical features and outcomes of estrogen receptor negative (ER-) and progesterone receptor positive (PgR+) breast cancer.

Methods: We retrospectively reviewed a well-characterized database of sequential patients diagnosed with early stage invasive breast carcinoma. Outcomes of interest were time to relapse (TTR) and overall survival (OS). Multivariable Cox proportional hazards analysis was conducted to assess the association of ER-/PgR+ with TTR and OS in comparison to ER+ and to ER- and PgR negative (ER-/PgR-) tumors irrespective of HER2 status. ER and PgR expression was conservatively defined as 10% or greater staining of cancer cells.

Results: 815 patients were followed for a median of 40.5 months; 56 patients (7%) had ER-/PgR+, 624 (77%) had ER+ and 136 (17%) had ER-/PgR- phenotypes. Compared with ER+ tumors, ER-/PgR+ tumors were associated with younger age (50 versus 59 years, p=0.03), high grade (50% versus 24%, p<0.001) and more frequent HER2 overexpression/amplification (43% versus 14%, p<0.001). TTR for ER-/PgR+ was intermediate between ER+ and ER-/PgR- tumors, but was not significantly different from ER+ tumors. Recurrences in the ER-/PgR+ and ER-/PgR- groups occurred early in follow-up while in ER+ tumors recurrences continued to occur over the duration of follow-up. OS of ER-/PgR+ was similar to ER+ tumors and better than that of ER-/PgR- tumors.

Conclusions: The ER-/PgR+ phenotype is associated with higher grade with HER2 overexpression/amplification and occurs more commonly in younger women. Risk of relapse and death more closely resembles ER+ than ER-/PgR- tumors suggesting this phenotype represents a group of more aggressive hormone receptor positive tumors.

Citing Articles

Tackling exosome and nuclear receptor interaction: an emerging paradigm in the treatment of chronic diseases.

Aswani B, Hegde M, Vishwa R, AlQahtani M, Abbas M, Almubarak H Mil Med Res. 2024; 11(1):67.

PMID: 39327610 PMC: 11426102. DOI: 10.1186/s40779-024-00564-1.

High tumour-infiltrating lymphocytes correlate with distinct gene expression profile and favourable survival in single hormone receptor-positive breast cancer.

Ciarka A, Kunc M, Popeda M, Lacko A, Radecka B, Braun M Contemp Oncol (Pozn). 2024; 28(1):75-83.

PMID: 38800535 PMC: 11117162. DOI: 10.5114/wo.2024.139375.

The role of modern parameters and their relationship with recurrence risk as assessed by Oncotype DX: real-world evidence.

Narvaez D, Nadal J, Nervo A, Costanzo V, Paletta C, Petracci F Ecancermedicalscience. 2024; 18:1664.

PMID: 38439804 PMC: 10911664. DOI: 10.3332/ecancer.2024.1664.

Visualized machine learning models combined with propensity score matching analysis in single PR-positive breast cancer prognosis: a multicenter population-based study.

Li C, Hui Y, Wei X, Yao P, Jia Y, Liu M Am J Cancer Res. 2023; 13(6):2234-2253.

PMID: 37424799 PMC: 10326595.

A prospective cohort study of clinical characteristics and outcomes in Chinese patients with estrogen receptor-negative/progesterone receptor-positive early breast cancer.

Fan Y, Zhong X, Wang Y, Wang Z, Luo T, Wang Y Breast Cancer Res Treat. 2023; 200(2):171-182.

PMID: 37199804 PMC: 10241679. DOI: 10.1007/s10549-023-06964-6.

References

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View

Bardou V, Arpino G, Elledge R, Osborne C, Clark G . Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003; 21(10):1973-9. DOI: 10.1200/JCO.2003.09.099. View

Brenner H, Hakulinen T . Are patients diagnosed with breast cancer before age 50 years ever cured?. J Clin Oncol. 2003; 22(3):432-8. DOI: 10.1200/JCO.2004.04.067. View

Colditz G, Rosner B, Chen W, Holmes M, Hankinson S . Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004; 96(3):218-28. DOI: 10.1093/jnci/djh025. View

Osborne C, Yochmowitz M, Knight 3rd W, McGuire W . The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980; 46(12 Suppl):2884-8. DOI: 10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u. View

Ravdin P, Green S, Dorr T, McGuire W, Fabian C, PUGH R . Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992; 10(8):1284-91. DOI: 10.1200/JCO.1992.10.8.1284. View

Martin M, Saceda M, Lindsey R . Regulation of estrogen receptor expression in breast cancer. Adv Exp Med Biol. 1993; 330:143-53. DOI: 10.1007/978-1-4615-2926-2_11. View

Pujol P, Daures J, Thezenas S, Guilleux F, Rouanet P, Grenier J . Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer. 1998; 83(4):698-705. View

Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

10.

Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales A . Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005; 123(1):21-7. DOI: 10.1309/4wv79n2ghj3x1841. View

11.

Cui X, Schiff R, Arpino G, Osborne C, Lee A . Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005; 23(30):7721-35. DOI: 10.1200/JCO.2005.09.004. View

12.

Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1659-72. DOI: 10.1056/NEJMoa052306. View

13.

Romond E, Perez E, Bryant J, Suman V, Geyer Jr C, Davidson N . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1673-84. DOI: 10.1056/NEJMoa052122. View

14.

Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2006; 25(1):118-45. DOI: 10.1200/JCO.2006.09.2775. View

15.

Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View

16.

Rakha E, El-Sayed M, Green A, Paish E, Powe D, Gee J . Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007; 25(30):4772-8. DOI: 10.1200/JCO.2007.12.2747. View

17.

De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W . Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?. J Clin Oncol. 2008; 26(2):335-6. DOI: 10.1200/JCO.2007.14.8411. View

18.

Hammond M, Hayes D, Dowsett M, Allred D, Hagerty K, Badve S . American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28(16):2784-95. PMC: 2881855. DOI: 10.1200/JCO.2009.25.6529. View

19.

Cserni G, Francz M, Kalman E, Kelemen G, Komjathy D, Kovacs I . Estrogen receptor negative and progesterone receptor positive breast carcinomas-how frequent are they?. Pathol Oncol Res. 2011; 17(3):663-8. DOI: 10.1007/s12253-011-9366-y. View

20.

Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378(9793):771-84. PMC: 3163848. DOI: 10.1016/S0140-6736(11)60993-8. View